Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Multi-omic characterization of lung tumors identify AKT and EZH2 as potential therapeutic targets in adenocarcinoma-to-squamous transdifferentiation
    Meeting Abstract

    Quintanal-Villalonga, Á.; Taniguchi, H.; Zhan, Y. A.; Hasan, M. M.; Chavan, S. S.; Uddin, F.; Allaj, V.; Manoj, P.; Shah, N.; Ciampricotti, M.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • XPO1 inhibition strongly sensitizes to first-line and second-line therapy in small cell lung cancer
    Meeting Abstract

    Quintanal‐Villalonga, Á.; Taniguchi, H.; Hao, Y.; Chow, A.; Zhan, Y. A.; Uddin, F.; Allaj, V.; Manoj, P.; Shah, N.; Chan, J. M.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Li, B. T.; Smit, E. F. F.; Goto, Y.; Nakagawa, K.; Udagawa, H.; Mazieres, J.; Nagasaka, M.; Bazhenova, L.; Saltos, A. N.; Felip, E.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study
    Meeting Abstract

    Janjigian, Y. Y.; Ajani, J. A.; Moehler, M.; Garrido, M.; Gallardo, C.; Shen, L.; Yamaguchi, K.; Wyrwicz, L.; Skoczylas, T.; Bragagnoli, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen
    Meeting Abstract

    van Cutsem, E.; Di Bartolomeo, M.; Smyth, E.; Chau, I.; Park, H.; Siena, S.; Lonardi, S.; Wainberg, Z. A.; Ajani, J. A.; Chao, J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • The role of oncology nurses in treatment-related adverse event management: An international online survey
    Meeting Abstract

    Fernández-Ortega, P.; Wittmer, B. A.; Pinheiro, N. A.; Belardi, P.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation
    Meeting Abstract

    Weiss, J.; Yaeger, R. D.; Johnson, M. L.; Spira, A.; Klempner, S. J.; Barve, M. A.; Christensen, J. G.; Chi, A.; Der-Torossian, H.; Velastegui, K.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Radioembolization with chemotherapy for colorectal liver metastases: A randomized, open-label, international, multicenter, phase III trial (EPOCH study)
    Meeting Abstract

    Mulcahy, M. F.; Salem, R.; Mahvash, A.; Pracht, M.; Montazeri, A. H.; Bandula, S.; Hermann, K.; Brown, E.; Zuckerman, D.; Wilson, G.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase III study of olaparib or cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (PSOC): Biomarker analyses from NRG-GY004
    Meeting Abstract

    Swisher, E.; Miller, A.; Kohn, E.; Brady, M.; Radke, M.; Pennil, C.; Khasnavis, N.; Buscema, J.; Tew, W.; Muller, C.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients
    Meeting Abstract

    Shoushtari, A. N.; Collins, L.; Espinosa, E.; Sethi, H.; Stanhope, S.; Abdullah, S.; Ikeguchi, A.; Ranade, K.; Hamid, O.
    Annals of Oncology (2021)

    Fulltext@MSK | Save